SCHEMBL801723

SCHEMBL801723

Cc1ccccc1-c1nc(Nc2n[nH]c3ccccc23)nc(-c2ccco2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.40
TRPA1 O75762 1/20 0.38
KDM1A O60341 1/20 0.37
CYP1A2 P05177 6/20 0.37
CYP3A4 P08684 6/20 0.37
CLK4 Q9HAZ1 4/20 0.37
CYP2D6 P10635 4/20 0.37
CYP2C19 P33261 4/20 0.37
ALOX15 P16050 4/20 0.37
HSD17B10 Q99714 4/20 0.37
USP2 O75604 2/20 0.37
EGFR P00533 1/20 0.37
TSHR P16473 3/20 0.36
PDE4B Q07343 1/20 0.36
PDE4D Q08499 1/20 0.36
FADS1 O60427 2/20 0.36
ADRA2A P08913 2/20 0.36
ALDH1A1 P00352 4/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12619966 0.85 USP1 (0.41) PDE5ACYP1A2CYP3A4CLK4CYP2D6
SCHEMBL801677 0.81 ALDH1A1 (0.46) PDE5ATRPA1CYP1A2CYP3A4CLK4
SCHEMBL802311 0.79 RAB9A (0.46) PDE5ATRPA1KDM1ACYP1A2CYP3A4
SCHEMBL802094 0.78 PIK3CA (0.45) CYP1A2CYP3A4CLK4CYP2D6TSHR
SCHEMBL801707 0.78 USP1 (0.50) PDE5ACYP1A2CYP3A4CLK4CYP2D6
SCHEMBL802694 0.77 CYP1A2 (0.50) CYP1A2CYP3A4CLK4CYP2D6HSD17B10
SCHEMBL802104 0.77 CYP1A2 (0.38) TRPA1CYP1A2CYP3A4CLK4CYP2D6
SCHEMBL801670 0.76 PIK3CA (0.43) TRPA1CYP1A2CYP3A4CLK4CYP2D6
SCHEMBL801711 0.76 GRM4 (0.41) TRPA1CYP1A2CYP3A4CLK4CYP2D6
SCHEMBL802691 0.75 GSK3A (0.46) PDE5ATRPA1CYP1A2CYP3A4CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 PDE5A 3100/4885TRPA1 4786/4885KDM1A 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.